[Slow release diltiazem as monotherapy in primary mild to moderate hypertension. A multicenter study].
To study the anti-hypertensive effect and tolerability of diltiazem SR in mild to moderate uncomplicated hypertensive patients. Out-patients (856) with mild to moderate uncomplicated hypertension (diastolic pressure between 95 and 114 mmHg) received 90 mg of diltiazem SR, per oral, twice a day for 20 days. After this period, the non-responders had the dosage increased to 120 mg twice a day while the responders were maintained with the same dosage for 20 days more. Significative number of patients (77.3%) normalized their blood pressure after 20 days on diltiazem SR therapy. The non-responders had the dosage increased to 120 mg bid for 20 more days. 72% of them achieved normal blood pressure. There were no important side effects with the dosage of 90 and 120 mg bid of diltiazem SR. Diltiazem SR may be a good option as initial monotherapy in the treatment of mild to moderate uncomplicated essential hypertension. It presented a reasonable side effects profile.